

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EVEREST MEDICINES

云 頂 新 耀

Everest Medicines Limited

雲 頂 新 耀 有 限 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1952)

Date of Board Meeting

The board of directors (the “**Board**”) of Everest Medicines Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that a meeting of the Board of the Company will be held on Wednesday, 24 August 2022, for the purpose of considering and approving the interim results of the Group for the six months ended 30 June 2022 and transacting any other business.

By Order of the Board

Everest Medicines Limited

Wei Fu

Chairman and Executive Director

Hong Kong, 12 August 2022

As at the date of this announcement, the Board comprises Mr. Wei Fu as Chairman and Executive Director, Dr. Kerry Levan Blanchard, Mr. Ian Ying Woo and Mr. Xiaofan Zhang as Executive Directors, Mr. Yubo Gong and Ms. Lan Kang as Non-executive Directors, and Mr. Bo Tan, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.